STOCK TITAN

Xylem (NYSE: XYL) SVP sells 4,269 shares and exercises 3,147 options

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported an open-market sale and an option exercise involving the company’s common stock. She sold 4,269 shares at a weighted average price of $117.46 per share, with individual trades ranging from $117.42 to $118.17.

On the same date, she exercised stock options to acquire 3,147 shares of common stock at an exercise price of $86.76 per share, fully exhausting that option grant. After these transactions, she directly owns 3,605 shares of Xylem common stock.

Positive

  • None.

Negative

  • None.
Insider McShane Geri-Michelle
Role SVP, CAO
Sold 4,269 shs ($501K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 3,147 $0.00 --
Exercise Common Stock 3,147 $86.76 $273K
Sale Common Stock 4,269 $117.46 $501K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 7,874 shares (Direct, null)
Footnotes (1)
  1. This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 4,269 Shares were executed at a range of prices from $117.42 to $118.17. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. The March 1, 2022 option grant vested 1,049 options on March 1, 2023, 1,049 options on March 1, 2024, and 1,049 options on March 1, 2025.
Shares sold 4,269 shares Open-market sale of Xylem common stock
Sale price (weighted average) $117.46/share Weighted average sale price, range $117.42–$118.17
Shares from option exercise 3,147 shares Common shares acquired via option exercise
Option exercise price $86.76/share Exercise or conversion price of stock options
Shares owned after transactions 3,605 shares Direct Xylem common stock holdings post-transaction
Options exercised from grant 3,147 options March 1, 2022 grant fully exercised for these shares
weighted average price financial
"This price represents the weighted average price per share of common stock"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
exercise price financial
"conversion_or_exercise_price": "86.7600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"option grant vested 1,049 options on March 1, 2023"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McShane Geri-Michelle

(Last)(First)(Middle)
C/O XYLEM INC.
301 WATER STREET SE

(Street)
WASHINGTON DISTRICT OF COLUMBIA 20003

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Xylem Inc. [ XYL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, CAO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026M3,147D$86.767,874D
Common Stock05/07/2026S4,269D$117.46(1)3,605D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$86.7605/07/2026M3,147 (2)03/01/2032Common Stock3,147$00D
Explanation of Responses:
1. This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 4,269 Shares were executed at a range of prices from $117.42 to $118.17. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
2. The March 1, 2022 option grant vested 1,049 options on March 1, 2023, 1,049 options on March 1, 2024, and 1,049 options on March 1, 2025.
/s/ Mike Nazario, by power of attorney for Geri-Michelle McShane05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Xylem (XYL) SVP Geri-Michelle McShane report?

Geri-Michelle McShane reported selling 4,269 Xylem shares in open-market trades and exercising stock options for 3,147 shares. These moves adjusted her direct holdings while also converting previously granted options into common stock.

How many Xylem (XYL) shares did the SVP sell and at what price?

She sold 4,269 Xylem common shares at a weighted average price of $117.46 per share. Individual trades occurred in a price range from $117.42 to $118.17, according to the transaction footnote.

What stock options did the Xylem (XYL) SVP exercise in this Form 4?

She exercised stock options covering 3,147 Xylem common shares at an exercise price of $86.76 per share. These options were from a March 1, 2022 grant that vested in three equal annual installments through March 1, 2025.

How many Xylem (XYL) shares does the SVP own after these transactions?

Following the reported sale and option exercise, Geri-Michelle McShane directly owns 3,605 Xylem common shares. This figure reflects her position after both the open-market sale and the conversion of options into shares.

Were the Xylem (XYL) insider sales executed at a single price or multiple prices?

The 4,269 Xylem shares were sold at multiple prices within a narrow range. The weighted average sale price was $117.46 per share, with actual trade prices ranging from $117.42 to $118.17.